Mode
Text Size
Log in / Sign up

73.4% of individuals with ADHD receive pharmacological treatment, meta-analysis findsAnalysis Shows High Rates of Medication Use for ADHD

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Interpret the 73.4% pooled prevalence cautiously due to high heterogeneity and wide prediction interval.

This systematic review and meta-analysis included 12 studies from Europe and worldwide, examining the prevalence of pharmacological treatment among individuals with clinically confirmed ADHD, including children, adolescents, and adults. The pooled prevalence of pharmacologically treated ADHD was 73.4% (95% CI: 63.4–81.5), with a prediction interval ranging from 29.6% to 94.5%, indicating substantial variation across settings. No significant geographic variation by country was found, and sex-stratified differences were not significant, though point estimates were slightly higher in males.

The authors note extremely high between-study heterogeneity, which limits the precision of the pooled estimate for direct clinical inference. The wide prediction interval reflects considerable variability across populations and settings. No safety data or comparator information was reported.

Clinicians should recognize that while a majority of individuals with ADHD receive pharmacological treatment, the prevalence varies widely. The pooled estimate is not intended for direct clinical application due to heterogeneity. These findings underscore the need for context-specific assessment of treatment rates.

How this fits prior evidence

This meta-analysis extends prior coverage on ADHD interventions by quantifying the prevalence of pharmacological treatment. Previous items highlighted long-term exercise and omega-3 supplementation as potential adjuncts for children with ADHD, but this review shows that pharmacotherapy remains the most common treatment, with 73.4% of individuals receiving it. The wide prediction interval (29.6%–94.5%) contrasts with the more uniform effects seen in exercise and omega-3 studies, emphasizing variability in pharmacological treatment rates across settings.

Researchers looked at data from 12 different studies to see how often people with Attention Deficit Hyperactivity Disorder (ADHD) use medication. The group included children, teenagers, and adults with confirmed diagnoses across various locations in Europe and around the world.

The analysis found that about 73.4% of individuals with ADHD were using pharmacological treatments. While some data suggested slightly higher numbers for males, there was no statistically significant difference between men and women. The study also found that the rate of medication use did not change significantly based on which country a person lived in.

It is important to note that these results come from a large collection of different studies with very different settings. Because of this variety, the 73.4% figure should be viewed as a general overview rather than a precise number for any specific clinic or region. You should talk to your doctor about what treatment options are best for your specific situation.

What this means for you:
About 73% of people with ADHD use medication, though rates vary by age and setting.

Common questions

How common is medication for people with ADHD?

The study found a pooled prevalence of 73.4% for individuals with ADHD who were using pharmacological treatments. This number represents a broad average from 12 different studies involving children, adolescents, and adults.

Is medication use for ADHD different between men and women?

The study found no significant difference in the use of pharmacological treatment between males and females. While some estimates were slightly higher for males, the difference was not large enough to be considered statistically significant.

Does the location of a person affect their access to ADHD medication?

The analysis found no significant variation in the prevalence of pharmacological treatment based on geographic location. This means the rates were similar across different countries included in the study.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
IntroductionAttention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental paediatric disorders and persists into adulthood, although it is frequently underdiagnosed and underrecognized in adult populations. In this context, the prevalence of pharmacologically treated individuals diagnosed with ADHD represents an important quality indicator for ADHD management.AimTo estimate the pooled prevalence of pharmacologically treated individuals with ADHD in different age groups in Europe and worldwide.MethodsA comprehensive search of PubMed/MEDLINE was conducted to identify relevant articles published up to October 4, 2024. The present systematic review and meta-analysis examined ADHD prevalence using clinically confirmed diagnoses and treatment data from official records. The exclusion criteria included studies that lacked clinical confirmation of ADHD and/or relied exclusively on parental reports for diagnostic or medication information. The prevalence of pharmacologically treated individuals with ADHD was calculated as a percentage, with a 95% confidence interval (CI). A meta-analysis was performed in R using a random-effects model. Heterogeneity was calculated using I². Prediction intervals were additionally computed to reflect the expected range of prevalence in future studies. Risk of bias was assessed for all included studies using a standardized, previously published methodology. The study was prospectively registered in PROSPERO (CRD42020200220) and adhered to the PRISMA guidelines for systematic review and meta-analysis (2020).ResultsThe systematic review identified 13 studies (12 studies included in the meta-analysis) with substantial variation in age-specific reporting. The pooled prevalence of pharmacologically treated ADHD was 73.4% (95% CI: 63.4–81.5), with extremely high between-study heterogeneity and wide 95% prediction interval (29.6%–94.5%), reflecting substantial variation across settings. The pooled prevalence estimate should be interpreted with caution due to substantial between-study heterogeneity and is not intended for direct clinical inference. Geographic analyses revealed no significant variation across countries. Sex-stratified analyses showed no significant difference between males and females, although point estimates were slightly higher in males.ConclusionThe prevalence of pharmacological treatment among individuals with ADHD appears to vary across age groups and settings Overall, findings indicate substantial variation in pharmacological treatment of ADHD by age, with consistently high heterogeneity limiting the precision of pooled estimates.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD42020200220.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.